CClinicalTrials.gg
CompletedNCT02020187Updated May 12, 2015

Aerobic Training in Patients With Congenital Myopathies

An interventional study of Exercise on a cycle-ergometer in Congenital Myopathy, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-05-12.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Congenital myopathies are clinical and genetic heterogeneous disorders characterized by skeletal muscle weakness. Most patients experience muscle weakness and fatigue throughout their life. However, progression of symptoms is rare. There are no specific treatments for congenital myopathies. Training has been shown to benefit several other muscle diseases with weakness, but the defect in congenital myopathies involves contractile proteins of the sarcomere, why the effect of training is uncertain in these conditions. The investigators will therefore investigate the effect cycle-ergometer training for 30 minutes, three times weakly, for ten weeks in 15 patients with congenital myopathy. Another 5-10 congenital myopathy patients, who do not train, will serve as controls for the trained patients. The study starts and ends with a test day, where efficacy based on VO2max, performance in functional tests and a questionnaire will be assessed.

Read the detailed description

10 weeks of cycle-ergometer training at home. Intensity at 70% of maximal VO2,max.

02

Conditions studied

  • Congenital Myopathy

Browse trials for

Keywords

  • Congenital myopathy
  • Exercise
03

In context

Muscular Diseases

280 studies on the registry are indexed under Muscular Diseases; 63 are open to participants now.

This study's enrollment of 16 is below the median of 34 across 157 interventional studies indexed under Muscular Diseases.

Browse Muscular Diseases studies →

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Danish patients with gene verified congenital myopathy

Exclusion criteria

Exclusion Criteria:

  • Patients who are to week to train at a cycle-ergometer for 10 weeks
  • Patients who have other health issues, which can disturb the interpretation of the efficacy
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Exercise

    10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.

    Other: Exercise on a cycle-ergometer

  • No intervention
    Controls

    Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.

Interventions

  • OtherExercise on a cycle-ergometer

    Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.

06

What researchers measure

Primary outcomes

  1. Efficacy based on VO2,max

    Difference in VO2,max from baseline to end of intervention.

    Time frame: 10 weeks

Secondary outcomes

  1. Level of Creatine Kinase

    Marker for exercise-induced muscle damage. Taken week 0, 3 and 10.

    Time frame: 10 weeks

  2. Intensity in maximal Watt

    Changes in the maximal intensity (watt) from baseline VO2,max test to after the intervention.

    Time frame: 10 weeks

  3. 6 minute walk test

    Changes in the walking distance from baseline to after the intervention.

    Time frame: 10 weeks

  4. SF-36 questionnaire

    Changes in SF-36 questionnaire from baseline to after the intervention.

    Time frame: 10 weeks

  5. A timed five-repetitions-sit-to-stand-test

    Changes in time from baseline to after the intervention.

    Time frame: 10 weeks

  6. A timed 14-step-stair-test

    Changes in time from baseline to after the intervention.

    Time frame: 10 weeks

  7. Dynamometry

    Changes in external force production from baseline to after the intervention. Dynamometry measurements are done at hip flexion, dorsal foot flexion, plantar foot flexion, knee flexion, knee extension and elbow flexion.

    Time frame: 10 weeks

07

Study locations

1 site
  • Neuromuscular Research Unit
    Copenhagen, 2100, Denmark
08

References and documents

Publications

  • Hedermann G, Vissing CR, Heje K, Preisler N, Witting N, Vissing J. Aerobic Training in Patients with Congenital Myopathy. PLoS One. 2016 Jan 11;11(1):e0146036. doi: 10.1371/journal.pone.0146036. eCollection 2016. PubMed 26751952 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02020187
Lead sponsor
Rigshospitalet, Denmark
Responsible party
Gitte Hedermann Pedersen (Medical student, Bsc, Rigshospitalet, Denmark) — Principal investigator
First posted
Dec 24, 2013
Start date
Sep 2013
Primary completion
Nov 2014
Completion
Nov 2014
Last update
May 12, 2015

Study contacts

Gitte H Pedersen, Bsc Medicine
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion